Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Annual Report 2021 is now available.

11/26/2021 | 12:10am EST

Astellas publish its annual report as an integrated report to enable deeper stakeholder understanding of Astellas' efforts to continuously create value for sustainable growth.
Annual Report 2021 is now available at the following link:
https://www.astellas.com/system/files/astellas_ar2021_en_20211126.pdf

In order to check the latest information on each item of the annual report, please visit the following link: https://www.astellas.com/en/investors/annual-report

Disclaimer

Astellas Pharma Inc. published this content on 26 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 November 2021 05:09:02 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
01/20ASTELLAS PHARMA : We posted the presentation material for media briefing on Digital Transf..
PU
01/20ASTELLAS PHARMA : Digital Transformation of Astellas Pharma(3,351KB)
PU
01/19Essa Pharma Commences Dosing in Phase 1/2 Clinical Trial of Prostate Cancer Combo Thera..
MT
01/16Glenmark Pharmaceuticals Unit Gets US FDA's Approval for Regadenoson Injection
MT
01/10Basilea Pharmaceutica - Strong Cresemba (isavuconazole) sales by Astellas in the U.S. t..
AQ
01/10Modalis Therapeutics and Astellas Pharma End Research Collaboration on Nervous System M..
MT
01/07Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US
MT
01/07Strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million..
DJ
01/07Modalis Announces Termination of Research Collaboration on MDL-204
CI
01/06Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration ..
AQ
More news
Financials
Sales 2022 1 330 B 11 697 M 11 697 M
Net income 2022 183 B 1 609 M 1 609 M
Net cash 2022 380 B 3 342 M 3 342 M
P/E ratio 2022 19,7x
Yield 2022 2,59%
Capitalization 3 583 B 31 486 M 31 512 M
EV / Sales 2022 2,41x
EV / Sales 2023 2,13x
Nbr of Employees 15 455
Free-Float -
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 933,50 JPY
Average target price 2 451,67 JPY
Spread / Average Target 26,8%
EPS Revisions
Managers and Directors
Kenji Yasukawa Executive Officer
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.1.74%30 923
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833